1. P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX). (23rd June 2022) Authors: Gupta, V.; Yacoub, A.; Verstovsek, S.; Mesa, R. A.; Harrison, C. N.; Barosi, G.; Kiladjian, J.-J.; Deeg, H. J.; Fazal, S.; Foltz, L.; Mattison, R. J.; Miller, C. B.; Parameswaran, V.; Hernandez, C.; Zhang, J.; Talpaz, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 932 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗